Alessandro D. Santin, MD | Authors


Efficacy Results for Trastuzumab in HER2-Positive Uterine Serous Carcinoma

March 27, 2018

Alessandro D. Santin, MD, a professor of obstetrics, gynecology, and reproductive sciences at Yale School of Medicine, discusses results of a randomized phase II trial of trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab (Herceptin) in advanced or recurrent uterine serous carcinomas that overexpress HER2/neu during the 2018 Society of Gynecologic Oncology Annual Meeting.